Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.59 |
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10852703 | 0.86 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL10760410 | 0.86 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL11117788 | 0.84 | MAPK1 (0.51) | SMN1; SMN2HTT | |
| SCHEMBL3078203 | 0.81 | ALDH1A1 (0.63) | RAB9ANPC1SMN1; SMN2HTTLMNA | |
| SCHEMBL26191682 | 0.80 | KDM4E (0.49) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL9750118 | 0.79 | NPC1 (0.81) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL12410301 | 0.79 | SMN1; SMN2 (0.72) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL5182822 | 0.78 | GAA (0.69) | RAB9ANPC1SMN1; SMN2GAAPKM | |
| SCHEMBL2574821 | 0.77 | CHEK1 (0.52) | HTTLMNAGAA | |
| SCHEMBL1649522 | 0.76 | EPHX1 (0.59) | RAB9ANPC1SMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070010516-A1 | Novel piperidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20060211707-A1 | Piperazine-alkyl-ureido derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-09-21 | — | — | US | disclosed |
| EP-1670470-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | disclosed |
| EP-1641776-A1 | NOVEL PIPERIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-04-05 | — | — | EP | disclosed |
| EP-1631565-A1 | PIPERAZINE-ALKYL-UREIDO DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | VELKER JORG (DE) | 2004-12-02 | — | — | US | disclosed |
| WO-2004099180-A1 | NOVEL PIPERIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099179-A1 | PIPERAZINE-ALKYL-UREIDO DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-18 | — | — | WO | disclosed |
| US-6815451-B2 | 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-11-09 | — | — | US | disclosed |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-06-10 | — | — | US | disclosed |
| WO-2004026836-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-04-01 | — | — | WO | disclosed |
| EP-1379523-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003048154-A1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO) -QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002076979-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-10-03 | — | — | WO | disclosed |
| US-4448780-A | N-(Lower-alkyl)-N'-[5-(pyridinyl)-2-pyridinyl]ureas and cardiotonic use thereof | STERLING DRUG INC. (US) | 1984-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | ADRA2C, ADRA1D, ADRB3 | RAB9A 1993/4885NPC1 598/4885SMN1; SMN2 2811/4885 |
| US-20060211707-A1 | Piperazine-alkyl-ureido derivatives | ADRA2C, UTS2R, ADRB2 | RAB9A 2743/4885NPC1 989/4885SMN1; SMN2 2314/4885 |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | UTS2R, NTSR2, NTSR1 | RAB9A 2566/4885NPC1 1463/4885SMN1; SMN2 2177/4885 |
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | RAB9A 2354/4885NPC1 2252/4885SMN1; SMN2 3430/4885 |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | P2RY4, P2RX4, REN | RAB9A 3371/4885NPC1 2301/4885SMN1; SMN2 3089/4885 |
| US-20070010516-A1 | Novel piperidine derivatives | UTS2R, VIPR2, NTSR2 | RAB9A 2144/4885NPC1 1725/4885SMN1; SMN2 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.